NASDAQ:IDXX - IDEXX Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $395.67
  • Forecasted Upside: -11.45 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$446.83
▼ -12.96 (-2.82%)
1 month | 3 months | 12 months
Get New IDEXX Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDXX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDXX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$395.67
▼ -11.45% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for IDEXX Laboratories in the last 3 months. The average price target is $395.67, with a high forecast of $422.00 and a low forecast of $375.00. The average price target represents a -11.45% upside from the last price of $446.83.
Buy
The current consensus among 3 investment analysts is to buy stock in IDEXX Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2020Credit Suisse GroupBoost Price TargetOutperform$415.00 ➝ $422.00Low
i
8/4/2020Credit Suisse GroupBoost Price TargetOutperform$300.00 ➝ $415.00Low
i
7/30/2020Stifel NicolausBoost Price TargetBuy$280.00 ➝ $375.00Low
i
7/20/2020Bank of AmericaBoost Price TargetBuy$300.00 ➝ $390.00Medium
i
5/1/2020Stifel NicolausBoost Price TargetBuy$266.00 ➝ $280.00Medium
i
11/1/2019GuggenheimSet Price TargetBuy$310.00Low
i
Rating by David Westenberg at Guggenheim
9/9/2019The Goldman Sachs GroupInitiated CoverageNeutral$277.00High
i
8/16/2019Credit Suisse GroupBoost Price TargetOutperform$282.00 ➝ $293.00Low
i
8/2/2019Canaccord GenuityReiterated RatingBuy$285.00Low
i
7/22/2019Stifel NicolausBoost Price TargetBuy$255.00 ➝ $295.00Low
i
7/1/2019Canaccord GenuityReiterated RatingBuy$280.00Low
i
6/21/2019Bank of AmericaSet Price TargetBuy$300.00Low
i
Rating by Michael Ryskin at Bank of America Co.
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$276.00Medium
i
5/2/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$255.00 ➝ $260.00Low
i
3/26/2019Canaccord GenuityLower Price TargetBuy$255.00 ➝ $254.00Low
i
11/5/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$270.00 ➝ $250.00Low
i
11/2/2018Bank of AmericaLower Price TargetBuy ➝ Buy$275.00 ➝ $235.00Low
i
8/17/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$255.00 ➝ $259.00Low
i
8/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$236.00Medium
i
7/10/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$225.00 ➝ $260.00High
i
6/21/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$228.00 ➝ $231.00Low
i
6/1/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$209.00 ➝ $228.00High
i
5/7/2018Canaccord GenuityReiterated RatingBuy ➝ Positive$215.00High
i
5/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$215.00 ➝ $225.00High
i
2/2/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$200.00 ➝ $220.00High
i
2/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$211.00High
i
1/29/2018Canaccord GenuityReiterated RatingBuy$210.00Low
i
1/16/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$200.00High
i
12/8/2017AegisReiterated RatingSellLow
i
Rating by B. Haynor at Aegis
10/24/2017Stifel NicolausReiterated RatingBuy$185.00N/A
i
10/6/2017Canaccord GenuityReiterated RatingBuy$180.00N/A
i
8/23/2017Bank of AmericaUpgradeNeutral ➝ Buy$175.00Low
i
8/22/2017Canaccord GenuityReiterated RatingBuy$180.00Low
i
8/21/2017Stifel NicolausReiterated RatingBuy$185.00Low
i
8/2/2017Stifel NicolausReiterated RatingBuy$185.00High
i
7/28/2017CL KingUpgradeNeutral ➝ Buy$200.00Medium
i
7/14/2017Stifel NicolausReiterated RatingBuy$185.00Low
i
6/13/2017Canaccord GenuityReiterated RatingBuy$180.00Low
i
Rating by Mark Massaro at Canaccord Genuity
5/31/2017AegisInitiated CoverageSell$118.00Low
i
5/1/2017Stifel NicolausBoost Price TargetBuy$150.00 ➝ $185.00Low
i
4/28/2017Canaccord GenuityReiterated RatingBuy$165.00 ➝ $180.00Low
i
Rating by Mark Massaro at Canaccord Genuity
2/14/2017Canaccord GenuitySet Price TargetBuy$145.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
2/3/2017Feltl & Co.DowngradeHold ➝ SellN/A
i
Rating by B. Haynor at Feltl & Co.
1/31/2017Canaccord GenuitySet Price TargetBuy$125.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
1/23/2017Canaccord GenuitySet Price TargetBuy$125.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
10/15/2016Canaccord GenuitySet Price TargetBuy$125.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
9/29/2016Bank of AmericaReiterated RatingNeutralN/A
i
8/22/2016Canaccord GenuityReiterated RatingBuy$120.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
8/16/2016Stifel NicolausBoost Price TargetBuy$120.00 ➝ $125.00N/A
i
8/3/2016Stifel NicolausReiterated RatingBuy$92.00 ➝ $120.00N/A
i
8/3/2016Northcoast ResearchUpgradeSell ➝ NeutralN/A
i
Rating by E. Snyder at Northcoast Research
8/2/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Mark Massaro at Canaccord Genuity
7/20/2016Canaccord GenuityBoost Price TargetBuy$90.00 ➝ $98.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
4/19/2016Canaccord GenuityReiterated RatingBuy$80.00 ➝ $85.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 ➝ $85.00N/A
i
4/1/2016CL KingInitiated CoverageNeutralN/A
i
3/21/2016Stifel NicolausBoost Price TargetBuy$80.00 ➝ $85.00N/A
i
Rating by Jonathan Block at Stifel Nicolaus
2/3/2016Credit Suisse GroupInitiated CoverageOutperform$80.00N/A
i
2/1/2016Piper Jaffray CompaniesReiterated RatingNeutral$73.00 ➝ $75.00N/A
i
2/1/2016Canaccord GenuityReiterated RatingBuy$80.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
1/31/2016William BlairReiterated RatingOutperformN/A
i
1/22/2016Canaccord GenuityReiterated RatingBuy$80.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
(Data available from 11/25/2015 forward)
IDEXX Laboratories logo
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $446.83
$446.46
$466.77

50 Day Range

MA: $435.03
$384.31
$478.10

52 Week Range

Now: $446.83
$168.65
$485.00

Volume

481,483 shs

Average Volume

542,104 shs

Market Capitalization

$38.11 billion

P/E Ratio

77.85

Dividend Yield

N/A

Beta

0.9